NCT02785250 - Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

May 31, 2025

Conditions

Recurrent Epithelial Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Peritoneal Cancer

Interventions

OTHER

DPX-Survivac

SubQ injection

DRUG

Cyclophosphamide

PO BID

DRUG

Epacadostat (INCB024360)

PO BID

Trial Locations (9)

Lenox Hill Hospital, New York

University of Pennsylvania, Philadelphia

Georgia Cancer Center at Augusta University, Augusta

Mary Crowley Cancer Research Center, Dallas

Stanford University, Palo Alto

Oregon Health & Sciences University, Knight Cancer Institute, Portland

Tom Baker Cancer Centre, Calgary

Princess Margaret Hospital, Toronto

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal